Cyramza 100mg Injection

About

Cyramza 100mg Injection contains Ramucirumab, a highly specific human monoclonal antibody designed to target and inhibit the vascular endothelial growth factor receptor 2 (VEGFR2). This receptor plays a critical role in angiogenesis, the process by which new blood vessels form to supply tumors with nutrients and oxygen, enabling their growth and spread. By blocking the binding of VEGF ligands to VEGFR2, Ramucirumab effectively disrupts this vital pathway, thereby inhibiting tumor vascularization and slowing disease progression. This targeted therapy represents a significant advancement in the management of specific advanced cancers.

Administered intravenously, Cyramza is typically used in combination with other chemotherapeutic agents to maximize its anti-tumor effects. Its use requires careful patient selection and continuous monitoring for potential side effects, particularly those related to its anti-angiogenic mechanism, such as hypertension, proteinuria, and an increased risk of bleeding or gastrointestinal perforation. Regular assessment of blood pressure and urine protein levels is essential to ensure patient safety and optimize treatment outcomes.

Uses

• Treatment of advanced gastric or gastroesophageal junction adenocarcinoma.
• Management of metastatic colorectal cancer.
• Treatment of metastatic non-small cell lung cancer.
• Used in combination with other chemotherapy regimens.

Directions For Use

Administered intravenously by a healthcare professional. Dosage and schedule are determined by the treating oncologist.

Benefits

• Targets a specific pathway crucial for tumor growth.
• Can extend progression-free survival.
• May improve overall survival in advanced cancers.
• Effective in combination with chemotherapy.
• Reduces tumor vascularization.
• Provides a targeted treatment option.

Side Effects

• Hypertension (high blood pressure)
• Proteinuria (protein in urine)
• Fatigue
• Diarrhea
• Abdominal pain
• Headache
• Peripheral edema
• Epistaxis (nosebleed)
• Thromboembolic events
• Gastrointestinal perforation
• Hemorrhage
• Infusion-related reactions

Safety Measures

• Alcohol - No specific contraindication, but excessive alcohol may worsen general health or interact with co-administered medications.
• Pregnancy - Contraindicated due to potential fetal harm; women of childbearing potential must use effective contraception.
• Breastfeeding - Not recommended; discontinue breastfeeding during treatment and for at least 3 months after the last dose.
• Liver - Use with caution in severe hepatic impairment; no specific dose adjustment guidelines, but close monitoring is advised.
• Kidney - Use with caution in severe renal impairment; no specific dose adjustment guidelines, but close monitoring is advised.
• Lung - Monitor for pulmonary hemorrhage, especially in lung cancer patients, and for other pulmonary adverse events.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.